Specialty Pharmacy

Hibernating innate lymphoid cells allows inflammation to persist in rheumatoid arthritis.

Top news of the day from across the health care landscape.

Understudied gene provides insight into how liver cancer cells gain the nutrition necessary to proliferate.

Younger patients with HIV have competing needs that distract them from fully engaging in care.

Legislative investigation seeks information from 7 drug makers on costs for MS medications.

Novel diabetes biosimilar shows similar safety, efficacy, and immunogenicity to the reference drug.

Brentuximab vedotin under evaluation for the treatment of cutaneous T-cell lymphoma.

The novel strategy could be more effective and less toxic than current chemotherapy drugs treating alternative lengthening telomere cancers.

Incentives for newly covered low-income patients may also reduce long-term costs.

Prolonged delay in antiretroviral treatment among patients necessitate scrutinization of the current guidelines for HIV therapy.

Pharmacy service was launched 6 years ago to help patients remain adherent to treatment regimens.

Carolyn Choate journeys 300 miles in a kayak to honor the pharmacologist who created the lifesaving aromatase inhibitor.

Top news of the week from Specialty Pharmacy Times.

Managing chronic pain after a cancer diagnosis remains a challenge.

The new compounds may lead to a highly effective, next-line treatment for estrogen receptor-positive breast cancer.

Hepatitis C elimination program screens more than 45K individuals in first 2 years of launch.

Top news of the day from across the health care landscape.

A gut microbe may play a role in the treatment of multiple sclerosis in the future.

Population growth and aging cause increase in disease burden from asthma and chronic obstructive pulmonary disease.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Olaparib tablets (Lynparza) approved as a maintenance treatment for patients with ovarian, fallopian, or primary peritoneal cancer.

Inotuzumab ozogamicin (Besponsa) granted FDA approval to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Biosimilar uptake in the United States still faces significant challenges.

Research finds that a robust pipeline of PsA agents will put pressure on Cosentyx.

Phase 3 program to examine novel gene therapy that treats the cause of hemophilia A.

Study is the first to provide evidence that proton-coupled amino acid transporters can be elevated in prostate cancer.

Age and tumor type most associated with initial insurance denial of cancer treatment, study finds.

Top news of the day from across the health care landscape.